Introduction
Methods
Protocol and registration
Eligibility criteria
Data sources and search strategy
Selection process
Data extraction
Assessing the methodological quality of the studies
Ratings of PROM development and content validity
Rating of the remaining measurement properties
Interpretability
Quality of evidence
Recommendations
Results
Study selection
Study characteristics
Category | PROM |
---|---|
Condition-specific | American Academy of Orthopaedic Surgeons Foot and Ankle Outcomes Questionnaire (AAOS-FAOQ) Ankle Fracture Outcome of Rehabilitation Measure (A-FORM) Foot and Ankle Ability Measure (FAAM) Lower Extremity Functional Scale (LEFS) Munich Ankle Questionnaire (MAQ) Olerud-Molander Ankle Score (OMAS) Self-reported Foot and Ankle Score (SEFAS) Visual Analogue Scale Foot and Ankle (VAS-FA) |
Generic | Short Musculoskeletal Function Assessment (SMFA) Trauma Expectation Factor Trauma Outcome Measure (TEFTOM) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), version 3.0, foot and ankle |
Patient-Reported Outcomes Measurement Information System Computer Adaptive Test (PROMIS CAT) | PROMIS-Lower Extremity (LE) CAT PROMIS-Physical Function (PF) CAT, version 1.2 |
PROM | Reference | Construct | Target population | (Sub)scale(s) / number of items | Response options | Range of scores/scoring | Original language | Available translationsa | Cost |
---|---|---|---|---|---|---|---|---|---|
American Academy of Orthopaedic Surgeons foot and ankle outcomes questionnaire, (1) the global foot and ankle scale, (2) the shoe comfort scale | Zelle 2017 | (1) Symptoms and functional status related to the foot and ankle (2) Ability to wear a variety of shoe types comfortably | Foot and ankle problems | The global foot and ankle scale / 20 items. The shoe comfort scale / 5 items | The global foot and ankle scale: 1–3, 1–5, 1–6, 1–7. The shoe comfort scale: Yes/no | 0–100% (best) | English | Spanish | Free, register at AAOS for scoring algorithm |
Ankle Fracture Outcome of Rehabilitation Measure v1.0 | McPhail 2014 | Life impacts (physical, social and psychological recovery) after ankle fracture | Ankle fracture | 15 items (summary only for 14 items) | 1–5 | 1–100 | English | ? | Contact developer |
Foot and Ankle Ability Measure | Schultz 2020 | Physical function (disability) | Musculoskeletal disorders of the feet and ankle | ADL + sports / 21 + 8 items | 0–4 | ADL 0–84 (worst), sports 0–32 (worst) | English | Chinese, Danish, Dutch, German, Japanese, Persian, Spanish, Thai, Turkish | Free |
Lower Extremity Functional Scale | Garratt 2018, Lin 2009, Repo 2017, Repo 2019 | Physical function (disability) | Musculoskeletal conditions or disorders in lower limb | 20 items | 0–4 | 0–80 (best) | English | Arabic, Brazilian Portuguese, Canadian, Chinese, Italian, Dutch, Finnish, French, Malaysian, Persian, Spanish, Turkish | Free |
Munich Ankle Questionnaire | Greve 2018 | Recovery/follow-up of ankle pathology | Ankle disorders | 3 subscales (pain, daily living/work and movement/ROM) / 12 items | Pain 1–10; Daily living 1–10; Work 1–7; Movement 1–3; ROM 0–20 | 106 points (best), 0–100% (best) | German | ? | ? |
Olerud-Molander Ankle Score | Büker 2017, Nilsson 2013, Garratt 2018, McKeown 2021, Ponzer 1999, Olerud Molander 1984, Turhan 2017, Shah 2007, Lash 2002 | Physical disability | Follow-up of ankle fracture | 1 scale / 9 items | Pain (0–25); Stiffness (0–10); Swelling (0–10); Stair climbing (0–10); Running (0–5); Jumping (0–5); Use of supports (0–10); Work/activity (0–20) | 0–100 (best) | English | Norwegian, Swedish, Turkish | Free, contact developer |
PROMIS LE CAT | Gausden 2018 | Physical function in patients with lower extremity conditions | Patients with lower extremity conditions | 79 items in question bank | 0–4 | Standardized score, mean 50 SD 10 | English | Danish, Dutch, Finnish, Portuguese (Brazil) | Depends on software |
PROMIS PF ver 1.2 CAT | Gausden 2018 | Physical function | General | 124 items in question bank | 0–4 | Standardized score, mean 50 SD 10 | English | Danish, Dutch, Finnish, Portuguese (Brazil) | Depends on software |
Self-Reported Foot and Ankle Score | Garratt 2018, Erichsen 2021 | Pain, function, other | Osteoarthritis and inflammatory arthritis of the ankle and outcome of ankle surgery | 12 items | 0–4 | Garratt: 12–60 (worst); Erichsen 0–48 (best) | Swedish | Danish, English, French, German, Spanish, Turkish | ? |
Short Musculoskeletal Functional Assessment | Obremskey 2007 | Physical function (dysfunction index) and impact of limitation of function (bother index) | Musculoskeletal conditions | 2 subscales: Dysfunction index (34 items) Bother index (12 items) | 1–5 | Converted to 0–100 (worst) | English | Chinese, Dutch, French, German, Korean, Japanese, Portuguese, Spanish, Swedish | Free |
Trauma Expectation Factor Trauma Outcomes Measure | Suk 2013, Fang 2020 | Pain, physical function, disability, injury satisfaction and overall satisfaction. 2 parts: TEF—expectations, TOM—outcome | General orthopedic trauma patients | 2 parts × 10 items per part, 5 domains, 1 scale | 0–4 | 0–40 (best) | English | Portuguese | ? |
Visual Analogue Scale Foot and Ankle | Repo 2018 | Not defined | Foot and ankle patients | Three subscales (function, pain, other complaints) / 20 items | VAS 0–100 mm | 0–100 (best) | German | English, Thai, Indian (Malayalam), Finnish | Free |
Western Ontario and McMaster Universities Osteoarthritis Index ver. 3.0 ankle/foot | Ponkilainen 2019 | Physical disability and symptoms | Osteoarthritis in foot/ankle | Three subscales (pain, stiffness and physical function) / 24 items | VAS 0–100 | Index 0–100 (worst) | English | 91 | License required |
PROM | References | N | Age, mean ± SD (range) | Sex, % female | Patient selection | Ankle Fx (%) | Surgical Tx (%) | Follow-up | Country | PROM Language | Response rate |
---|---|---|---|---|---|---|---|---|---|---|---|
AAOS-FAOQ | Zelle 2017 [39] | 83; test–retest: 63 | ? | ? | Ankle or foot disorder | > 49 | ? | ? | Mexico | Spanish | 83% (83/100) |
A-FORM v1.0 | McPhail 2014 [41] | 41 | Median 37 (IQR: 28) | 27 | Ankle Fx | 90 | 46 | 12–16 weeks | ? | English | 80% (41/51) |
FAAM | Schultz 2020 [51] | 27 | 57 | Ankle Fx, pilon, distal tibia | 78 | 100 | 42 weeks ± 4.2 | USA | English | ? | |
LEFS | Lin 2009 (1) [44] | 306 | 45 ± 16 | 50 | Ankle Fx | 100 | 57 | 26 weeks | Australia | English | ? |
LEFS | Lin 2009 (2) [44] | 60 | 49 ± 17 | 52 | Ankle Fx | 100 | ? | 26 weeks | Australia | English | ? |
LEFS | Lin 2009 (3) [44] | Baseline to 4 weeks: 233; Baseline to 24 weeks: 90 | ? | ? | Ankle Fx | 100 | ? | 4 and 24 weeks | Australia | English | ? |
LEFS | Repo 2017 [34] | 166 | 55 ± 16 | 53 | Foot or ankle surgery | > 73 | 100 | Mean: 4 years (range: 0–14) | Finland | Finnish | 22% (166/747) |
LEFS | Repo 2019 [37] | 182 | 55 ± 16 | 54 | Foot or ankle surgery | 73 | 100 | 3.2 years ± 9.6 | Finland | Finnish | ? |
MAQ | Greve 2018 [52] | 148 | Median 45 ± 16 | 53 | Ankle disorders | 51 | ? | 4 months | Germany | German | Test–retest: 73% (118/162); construct validity: 88% (142/162); responsiveness: 57% (92/162) |
OMAS | Büker 2017 [53] | 91 | 42 ± 13 (20–60) | 28 | Ankle Fx | 100 | 100 | 28 ± 8.9 months | Turkey | Turkish | ? |
OMAS | Lash 2002 [54] | 74 | 49 | 70 | Ankle Fx | 100 | 69 | 2 years | New Zealand | English | 52% (74/141) |
OMAS | McKeown 2021 [45] | 620 | 46 ± 17 (18–94) | 56 | Ankle Fx | 100 | 53 | 3.5 months | UK | English | ? |
OMAS | Nilsson 2013 (1) [50] | 42 | 42 ± 14 | 55 | Ankle Fx, | 100 | 100 | 12 months | Sweden | Swedish | ? |
OMAS | Nilsson 2013 (2) [50] | 6 months: 105; 12 months: 99 | 44 ± 14 | 60 | Ankle Fx, | 100 | 100 | 12 months | Sweden | Swedish | ? |
OMAS | Nilsson 2013 (3) [50] | 46 | 43 ± 14 | 56 | Ankle Fx, | 100 | 100 | 12 months | Sweden | Swedish | ? |
OMAS | Olerud-Molander 1984 [33] | 90 | ? | ? | Ankle Fx, multicomponent Fxs, | 100 | 100 | ? | ? | ? | ? |
OMAS | Ponzer 1999 [55] | 41 | 41 ± 12 | 54 | Ankle Fx | 100 | 100 | 27 | Sweden | ? | 77% (41/53) |
OMAS | Shah 2007 [38] | 69 | 51 (20–81) | 62 | Ankle Fx | 100 | 100 | 5 years | UK | English | 81% (69/85) |
OMAS | Turhan 2017 [36] | 100 | 42 ± 18 (16–81) | 49 | Ankle Fx | 100 | 57 | 4.3 years | Turkey | Turkish | ? |
OMAS, LEFS, SEFAS | Garratt 2018 [40] | 567; test–retest: 182 | 58 (22–91) | 57 | Ankle Fx | 100 | 100 | 4.3 years, IQR: 3.9–5.1 | Norway | Norwegian | 59% (567/959); test–retest: 60% (182/299) |
PROMIS PF v1.2/LE CAT | Gausden 2018 [56] | 132 | 47 ± 18 | 60 | Ankle Fx | 100 | 100 | 12 | USA | English | 85% (132/156) |
SEFAS | Erichsen 2021 (1) [43] | 10 | ? | ? | Ankle disorder | ? | ? | ? | Denmark | Danish | |
SEFAS | Erichsen 2021 (2) [43] | 125 | 49 (18–81) | 55 | Ankle-related Fxs | 68 | 79 | 6 weeks | Denmark | Danish | 87% (125/143) |
SEFAS | Erichsen 2021 (3) [43] | 85 | 53 (19–81) | 59 | Ankle-related Fxs | 100 | 69 | 7.2 weeks | Denmark | Danish | 59% (85/143) |
SMFA | Obremskey 2007 [57] | 127 | 48 ± 18 (17–85) | 58 | Ankle Fx, | 100 | 100 | Mean: 27 ± 17 months (range: 6–64 months) | ? | English | ? |
TEFTOM | Fang 2020 [58] | 193 | 44 (17–81) | 47 | Ankle Fx | 90 | 100 | 12 months | Spain, Germany, Switzerland, China, India | German, Spanish, Chinese | ? |
TEFTOM | Suk 2013 [42] | 148 | 41 ± 15 | 45 | Isolated ankle or distal tibia Fx | 90 | 100 | 20 months | Brazil, Canada, USA | Portuguese, English | 74% (148/201) |
VAS-FA | Repo 2018 [35] | 165 | 56 ± 16 | 55 | Foot or ankle surgery | 83 | 100 | Mean: 4.3 years ± 4.7 | Finland | Finnish | ? |
WOMAC | 130 | 56 ± 17 | 57 | Ankle Fx | 100 | 100 | Mean: 4 years (range: 1 month-14 years) | Finland | Finnish | 61% (130/212) |
Measurement properties
PROM: A-FORM | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
References | Content validity | Structural validity | Internal consistency | Reliability | Measurement error | H testing for construct validity | Responsiveness | |||||||
MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | |
McPhail 2014 [40] | I | + |
Summarized results | NA | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall rating | Sufficient | |||||||||||||
Quality of evidence | Very low; PROM development study inadequate, only reviewers’ ratings |
PROM: LEFS | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
References | Content validity | Structural validity | Internal consistency | Reliability | Measurement error | H testing for construct validity | Responsiveness | |||||||
MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | |
Garratt 2018 [49] | V | ( +) CFA: CFI 0.99/TLI 0.99/RMSEA 0.091 | D | ( +) Cα = 0.96 | A | ( +) ICC: 0.91 | A | (?) SDC: 12.5 | A | H met: 7 H unmet: 1 | ||||
Garratt 2018 [49] | D | H unmet: 1 | ||||||||||||
Lin 2009 (1) [42] | V | (-) | D | ( +) Cα = 0.90–0.96 | ||||||||||
Lin 2009 (2) [42] | V | H met: 2 | ||||||||||||
Lin 2009 (3) [42] | D | H met: 2 AUC: 0.79 and 0.84 | ||||||||||||
Repo 2017 [34] | D | + | A | ? | D | Cα = 0.96 | A | ( +) ICC: 0.93 | A | ? | A | H met: 4 | ||
Repo 2019 [37] | A | - |
Summarized results | Only comprehensibility | ± | Cα: 0.90–0.96 | ICC: 0.91–0.93 | SDC: 12.5 MIC: unknown | H met: 13 H unmet: 2 | H met: 2 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall rating | NA | Inconsistent | Sufficient | Sufficient | Indeterminate | Sufficient 87% confirmed | Sufficient | |||||||
Quality of evidence | NA | NA | NA; due to lack of evidence for sufficient structural validity | High; two studies of adequate quality | NA | High | Low |
PROM: OMAS | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reference | Content validity | Structural validity | Internal consistency | Reliability | Measurement error | H testing for construct validity | Responsiveness | |||||||
MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | |
Büker 2017 [44] | V | ( +) Cα = 0.76 | I | ( +) ICC: 0.94 | A | H met: 6 | ||||||||
Lash 2002 [45] | I | NA | ||||||||||||
Garratt 2018 [49] | V | ( +) CFA: CFI 0.99/TLI 0.98/RMSEA 0.087 | V | ( +) Cα = 0.82 | A | ( +) ICC: 0.92 | A | (−) SDC: 19.0; MIC: 9.7a | A | H met: 6; H unmet: 2 | ||||
Garratt 2018 [49] | D | H unmet: 1 | ||||||||||||
McKeown 2021 [46] | A | (?) | V | ( +) Cα total: 0.76 | A | H met: 8; H unmet: 4 | ||||||||
Nilsson 2013 (1) [47] | V | ( +) Cα = 0.76 | D | ( +) ICC: 0.94 | D | (−) SDC: 12.0; MIC: 9.7a | ||||||||
Nilsson 2013 (2) [47] | I | NA | ||||||||||||
Nilsson 2013 (3) [47] | A | H met: 5 | ||||||||||||
Olerud-Molander 1984 [33] | I | NA | ||||||||||||
Ponzer 1999 [48] | D | H met: 8; H unmet: 2 | ||||||||||||
Shah 2007 [38] | A | H met: 1; H unmet: 1 | ||||||||||||
Turhan 2017 [36] | D | + | V | ( +) Cα = 0.84 | I | ( +) ICC: 0.98 | I | ( +) SDC: 9.1; MIC: 9.7a | A | H met: 2; H unmet: 2 |
Summarized results | Only comprehensibility | Unidimensional | Cα: 0.76–0.84 | ICC: 0.92–0.98 | SDC: 9.1–19.0; MIC: 9.7a | H met: 36; H unmet: 12 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall rating | NA | Sufficient | Sufficient | Sufficient | Insufficient | Sufficient 75% confirmed | ||||||||
Quality of evidence | NA | High; one very good study | High; multiple very good studies; consistent results | Moderate; only one study of adequate quality | Very low; only one study of adequate quality, one MIC, and indirectness (follow-up time 4.3 years vs. 16 weeks) | High; multiple studies of adequate quality |
PROM: SEFAS | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
References | Content validity | Structural validity | Internal consistency | Reliability | Measurement error | H testing for construct validity | Responsiveness | |||||||
MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | MQ | R | |
Erichsen 2021 (1) [51] | I | + | ||||||||||||
Erichsen 2021 (2) [51] | V | ( +) Cα = 0.93 | D | H unmet: 1 | ||||||||||
Erichsen 2021 (3) [51] | I | ( +) ICC: 0.93 | I | (−) SDC: 6.8; MIC: 5 | ||||||||||
Garratt 2018 [49] | V | ( +) CFA:CFI 0.99/TLI 0.99/RMSEA 0.063 | V | ( +) Cα = 0.93 | A | ( +) ICC: 0.93 | A | (−) SDC: 6.6; MIC: 5b | A | H met: 6; H unmet: 2 |
Summarized results | Only comprehensibility rated | Unidimensional | Cα = 0.93 | ICC: 0.93 | SDC: 6.6–6.8; MIC: 5b | H met: 6; H unmet: 3 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Overall rating | NA | Sufficient | Sufficient | Sufficient | Insufficient | Sufficient 75% confirmed (based on at least adequate MQ: H met: 6, H unmet: 2) | ||||||||
Quality of evidence | NA | High | High | Moderate; only one study of adequate quality | Very low; MIC based on only one study and not adequately performed | Moderate |